Diagnos Medical Systems

07/29/2025

AI Ophthalmology Hits Inflection Point

The global AI ophthalmology market just crossed US$209M in 2024, with projections showing explosive growth ahead. According to Yahoo Finance, "AI applications in ophthalmology are set to revolutionize diagnosis and treatment, potentially saving healthcare systems billions while improving patient outcomes."

Market Tailwinds 📈

The numbers tell a compelling story:
• US$209M current market size accelerating rapidly
• 40M+ annual retinal imaging tests creating massive data opportunity
• Aging demographics driving 2X growth in 65+ population by 2050
• 12% decline in optometrists creating critical care gap

The DIAGNOS Advantage – Real Revenue, Real patients, Real Partnerships

While giants chase tomorrow's opportunity, DIAGNOS is delivering today:
✓ 16 countries, 140 clinics, 400K patients already screened
✓ Submitted FDA Pre-Submission Application
✓ Blue-chip validation: 3-year Essilor agreement + New Look Canada rollout
✓ Government traction: Applied for Quebec Health Screening Initiative

The math is clear: Diagnos AI technology + commercial proof points = significant opportunity

The convergence is clear: exploding market demand meets proven AI technology meets commercial ex*****on. With major catalysts ahead (Essilor scale-up, government contracts, new test launches), DIAGNOS represents a rare opportunity

07/16/2025

🚀 Milestone Alert
DIAGNOS (TSX-V: ADK | OTCQB: DGNOF) has just filed its FDA Pre-Submission for the CARA AI retinal-analysis platform. This marks the first strategic step toward U.S. regulatory clearance and commercial entry into the US optometry market.

Why this matters (at a glance):
• Massive unmet need: 88 M+ comprehensive eye exams annually in the U.S. and AI can help boost accuracy & throughput.
• Clinical depth: CARA flags diabetic & hypertensive retinopathy, AMD, and other micro-vascular changes in seconds.
• Real-world muscle: 450 k+ retinal images from 16 countries train the model for diverse populations.

What’s next?
This submission is step 1 toward unlocking the large U.S. optometry market. Stay tuned as we work with regulators and partners to bring CARA into clinics across North America.

👉 https://lnkd.in/enFbA8a5
💬 Have questions about the tech or partnership opportunities? Drop them below.

This link will take you to a page that’s not on LinkedIn

07/14/2025

AI-assisted Diagnostics with Real-World Traction: Deep Dive with CEO, André Larente.

Diabetic retinopathy is one of many vision-threatening diseases that can be caught early if clinicians have the right tools.

Diagnos’ AI-powered platform, CARA, reads retinal scans in under two seconds with specialist-level accuracy. It's already scaled across 16 countries, 140 clinics, and 400,000+ patients. Diagnos is moving forward with commercial pilots underway at New Look and a three-year agreement with EssilorLuxottica, the world’s largest optical network.
We are building a capital-efficient, high-margin diagnostics engine that spans both public health and retail care.

Watch our new 9-minute deep-dive video on how this our company is positioned to capture a multibillion-dollar market.

Connect with us to learn more about Diagnos’ impact in AI-assisted vision diagnostics.

09/28/2021

Diagnos (ADK) CEO Andre Larente - Presentation, Deep Dive & Q&A

Presentation, Deep Dive & Q&A with CEO Andre Larente Diagnos (ADK)Wed, Sep 22Diagnos is dedicated to early detection of critical health problems based on its...

09/23/2021

André Larente provides an update on the ‘exponential growth’ of the -based platform https://youtu.be/cGuKOxSRPJA $ADK.V $DGNOF

In a recent InvestorIntel interview, Tracy Weslosky spoke with André Larente, President of Diagnos Inc. (TSXV: ADK | OTCQB: DGNOF) about Diagnos’ recent mile...

09/16/2021

DIAGNOS Announces a Multi-Year Contract with Juarez Health & Medical Tourism Cluster

Detailed price information for Diagnos Inc (ADK-X) from The Globe and Mail including charting and trades.

09/14/2021

Diagnos Inc. Partners with Cielo Vista Eye Clinic in Mexico to offer CARA services to at-risk patients with diabetes.

12/10/2019

Press Release!!

DIAGNOS Announces Collaborative Agreement in the North American Borderplex Region

Find OUT More--->https://bit.ly/343y1V3

11/14/2019

Our Chief Medical Office is at the 20th congress of diabetes of Algeria!

10/29/2019

Press Release!

DIAGNOS and its Local Partner Selected Following a Competitive Bid from the Mexican Government!

Find OUT more--->

07/01/2019

Invitational to Panama’s President Oath Ceremony.- Mr. André Larente, President and CEO of Diagnos, and Mr. Guillermo Moreno, Vice President, were personally invited to the event and strengthening ties after one year and half showing case Diagnos’ AI technology to prevent blindness caused by diabetes.

06/20/2019

Press Release!

DIAGNOS Announces an Extension to the Diabetic Retinopathy Screening Services Assisted by Artificial Intelligence (AI) at the CHUM!

“This technological showcase is very important to us. We can demonstrate our expertise to our future Canadian
and international clients. We can present the precision of our algorithms in the detection and classification of the patients in order of the severity of the disease. This showcase is also helping us to understand how healthcare professionals integrate Artificial Intelligence in their practice,” said Yves-Stéphane Couture , Vice President at DIAGNOS.

DIAGNOS has screened to date more than 275,000 diabetic patients. Thanks to the support of the Government of Quebec and our collaboration with the CHUM, this technological showcase will allow DIAGNOS to demonstrate our expertise in the province. We strongly believe this project will also help set up extensive screening campaigns in other Canadian provinces and in the United States.

Find OUT More -->https://bit.ly/2RptB6o